Abstract
Purpose
Elevated lipoprotein(a) [Lp(a)] levels are a recognized risk factor for cardiovascular
disease; however, little is known about their effects on venous thromboembolism.
Methods
We conducted a case-control study of 603 adult patients with a history of venous thromboembolism
(at least 6 months after the acute event) and 430 healthy subjects. We measured Lp(a),
homocysteine, and antithrombin levels, factor V Leiden and factor II (prothrombin)
polymorphisms, and anticardiolipin antibodies.
Results
Lp(a) levels >300 mg/L were found in 24% (n = 146) of the patients and in 13% (n =
58) of the controls (P = 0.005). In a multivariate analysis adjusted for acquired and hemostasis-related
risk factors, there was an independent association between elevated (>300 mg/L) Lp(a)
levels and venous thromboembolism (odds ratio = 2.1; 95% confidence interval: 1.4
to 3.2; P = 0.002). These results were confirmed in the 341 patients with idiopathic venous
thromboembolism, as well as in those with recurrent thromboembolism.
Conclusion
These results show that Lp(a) is an independent risk factor for venous thromboembolism
in adults, suggesting that it may be involved in the pathogenesis of idiopathic and
recurrent disease.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The American Journal of MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- A prospective study of the incidence of deep vein thrombosis within a defined urban population.J Intern Med. 1992; 232: 155-160
- Deep vein thrombosis and pulmonary embolism in the general population.Arch Intern Med. 1997; 157: 1665-1670
- Deep vein thrombosis.Lancet. 1999; 353: 479-485
- Blood coagulation.Lancet. 2000; 355: 1627-1635
- Hyperhomocysteinemia and venous thrombosis: a meta-analysis.Thromb Haemost. 1998; 80: 874-877
- Lp(a) as a strong indicator for cerebrovascular disease.Stroke. 1986; 17: 942-945
- Immunochemical quantification of human plasma Lp(a) lipoprotein.Lipids. 1974; 9: 15-26
- Lp(a) lipoprotein and pre-beta-1 lipoprotein in patients with coronary heart disease.Clin Genet. 1974; 6: 230-235
- Relation of serum Lp(a) concentration and apoLp(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia.N Engl J Med. 1990; 322: 1494-1499
- Relation of lipid and Lp(a) to ischemic stroke.J Clin Neurosci. 2002; 2: 127-132
- Lp(a): intrigues and insights.Curr Opin Lipidol. 1999; 10: 225-236
- cDNA sequence of human apoLp(a) is homologous to plasminogen.Nature. 1987; 300: 132-137
- Increased Lp(a) levels as an independent risk factor for venous thromboembolism.Blood. 2000; 96: 3364-3368
- Increased Lp(a) is an important risk factor for venous thromboembolism in childhood.Circulation. 1999; 100: 743-748
- ApoLp(a) concentrations are not related to the risk of venous thrombosis.Blood Coagul Fibrinol. 1991; 2: 595-599
- Lp(a) concentration is not associated with venous thromboembolism in a case control study.Haematologica. 1999; 84: 726-729
- Lp(a), cholesterol and triglycerides in women with venous thromboembolism.Blood Coagul Fibrinol. 2000; 11: 225-229
- Lipoproteins, anticardiolipin antibodies and thrombotic events in rheumatoid arthritis.Clin Exp Rheumatol. 1996; 14: 593-599
- Lipoprotein(a) predicts the risk of thrombogenic complications in nephrotic syndrome [letter].Nephron. 1992; 61: 122
- The effect of aggressive and moderate lowering of LDL-cholesterol and low-dose anticoagulation on plasma lipids, apolipoproteins and lipoprotein families in post coronary artery bypass graft trial.Atherosclerosis. 1999; 146: 369-372
- Tissue factor and homocysteine levels in ischemic heart disease are associated with angiographically documented clinical recurrences after coronary angioplasty.Thromb Haemost. 2000; 83: 826-832
- Lp(a) excess and coronary heart disease.Arch Intern Med. 1997; 157: 1170-1176
- The role of Lp(a) in atherogenesis and thrombosis.Annu Rev Med. 1996; 47: 423-442
- Quantification of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease.Ann Intern Med. 1994; 120: 1012-1025
- A prospective study of lipoprotein(a) and the risk of myocardial infarction.JAMA. 1993; 270: 2195-2199
- Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors.Blood. 2001; 97: 858-862
- Transient changes of serum Lp(a) as an acute phase protein.Atherosclerosis. 1989; 78: 145-150
- Increased Lp(a) levels are not a steady prothrombotic defect [letter].Blood. 2001; 98: 1993-1994
- Lp(a) and lipids in relation to inflammation in rheumatoid arthritis.Clin Rheumatol. 2000; 19: 324-325
- High Lp(a) levels in chronic hemodialysis patients are closely related to the acute phase reaction.Thromb Haemost. 1995; 74: 1020-1024
- Lp(a) in Behcet's disease as an indicator of disease activity and in thrombotic complications.Eur J Ophthalmol. 2001; 11: 62-65
- Lp(a): an acute-phase reactant?.Chem Phys Lipids. 1994; 67-68: 411-417
- Dominant negative effect of TGF-beta1 and TNF-alpha on basal and IL6 induced Lp(a) and apoLp(a) mRNA expression in primary monkey hepatocyte cultures.Arterioscler Thromb Vasc Biol. 1998; 18: 984-990
- Lp(a), plasmin modulation, and atherogenesis.Thromb Haemost. 1995; 74: 382-386
- Lp(a) levels and isoforms and fibrinolytic activity in postmenopause: influence of hormone replacement therapy.Thromb Haemost. 1999; 81: 104-110
- Hormone regulation of Lp(a) levels: effects of estrogen replacement therapy on Lp(a) and acute phase reactants in postmenopausal women.Arterioscler Thromb Vasc Biol. 1997; 17: 1822-1829
- Fibrinolysis and Lp(a) in women with coronary artery disease. Influence of hormone replacement therapy.Haematologica. 2001; 86: 92-98
Article info
Publication history
Accepted:
June 26,
2003
Received in revised form:
June 26,
2003
Received:
April 23,
2002
Identification
Copyright
© 2003 Excerpta Medica Inc. Published by Elsevier Inc. All rights reserved.
